NCT07178522View on ClinicalTrials.gov

A Study to Evaluate the Immunogenicity and Safety of an EV71 Vaccine (Envacgen®) in Children Aged 6 to <10 Years Compared to Children Aged 2 to <6 Years

PHASE3RecruitingINTERVENTIONAL
Enrollment

378

Participants

Timeline

Start Date

June 25, 2025

Primary Completion Date

February 1, 2026

Study Completion Date

July 1, 2026

Conditions
Enterovirus 71 Inactivated Vaccine
Interventions
BIOLOGICAL

Envacgen®

Subjects are to receive a 0.5 mL IM injection of Envacgen®. Study drug is administered on Day 1 and Day 57 of the study.

Trial Locations (3)

Unknown

RECRUITING

National Taiwan University Hospital Hsin-Chu Branch, Hsinchu

RECRUITING

National Taiwan University Hospital, Taipei

RECRUITING

Chang Gung Medical Hospital Linkou, Taoyuan District

Sponsors
All Listed Sponsors
lead

Medigen Vaccine Biologics Corp.

INDUSTRY

NCT07178522 - A Study to Evaluate the Immunogenicity and Safety of an EV71 Vaccine (Envacgen®) in Children Aged 6 to <10 Years Compared to Children Aged 2 to <6 Years | Biotech Hunter | Biotech Hunter